地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:17754422825
邮箱:sales@amyjet.com

艾美捷科技代理Sterlitech全系列产品。
主要产品包括:(1)过滤器:滤膜、注射器过滤器和胶囊过滤器;(2)过滤器支架:各种过滤器支架配置;(3)膜/工艺开发:聚合物平板膜、陶瓷膜,台架横向/切向流动试验室和过滤设备;(4)实验室设备:真空泵、流体输送/储存系统、加热板/搅拌器等。
<点击并打开产品列表
http://www.amyjet.com/Index/lists/catid/27/kid/70.html
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Sterlitech全系列滤膜、滤器"> 艾美捷科技代理Sterlitech全系列滤膜、滤器

Innovative Research of America(IRA) 是一家致力研发于药物定量定时缓释系统的专业化公司,又称Matrix-Driven Delivery (MDD) 给药系统。该给药系统由一个可生物吸收的基质组成,含有定量可控的活性给药成分,可以以设定的剂量在一定时间范围内进行给药。
Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives. However, most scientists continue to labor with unreliable injectables to conduct their research.
Matrix-Driven Delivery (MDD) Pellet(MDD片剂)的优势
Saves time
Ready-to-implant
Insures controlled product release over time
Avoids "peak and valley" effects
Guarantees consistent product preparation
Extends product life against spontaneous breakdown
Extends product life against host-related breakdown
Minimizes experimental variables
Insures safety of the experimenter
Reduces neurophysiological trauma to animal/no excessive handling
Generates more meaningful and reproducible results
Superior to conventional delivery methods
Enhances experimental efficiency
Frees valuable time for creative research
Saves money
Innovative Research of America的主要产品包括:
ANTIBIOTICS
ANTI-INFLAMMATORY AGENTS
ANTI-NEOPLASTICS
CATECHOLAMINES & RELATED PRODUCTS
CORTICOIDS & DIURETICS
ESTROGENS & ANTI-ESTROGENS
FATTY ACIDS
MISCELLANEOUS PRODUCTS
NUCLEOTIDE RELATED PRODUCTS
PLACEBO
PROGESTINS
PROSTAGLANDINS
THYROIDS
VITAMINS
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Innovative Research of America"> Innovative Research of America
美国Jackson ImmunoResearch Laboratories, Inc. 专业致力于亲合纯化的第二抗体和纯化的 免疫球蛋白的生产和偶联。其产品深受广大研究人员的认可,销售范围遍布全球, 领域包括植物,动物和生物医学研究。公司成立于1982年,公司创业者具有深厚的专业背景:细胞生物学,蛋白化学,微生物学,免疫学。公司自创立初,就将为其 他研究人员提供最新最全的二抗作为公司的持续发展目标。
Jackson ImmunoResearch Laboratories, Inc. specializes in the production and conjugation of affinity-purified secondary antibodies and purified immunoglobulins. Our products are sold primarily to scientists in universities and research institutes throughout the world who are conducting research in the plant, animal, and biomedical sciences.
Jackson Immunoresearch Laboratories的主要产品包括:
Whole IgG Affinity-Purified Antibodies
F(ab')₂ Fragment Affinity-Purified Antibodies
Fab Fragment Affinity‑Purified Antibodies
FabuLight™ - Affinity-Purified Fab Anti-Fc Fragment Specific Antibodies
Anti-Mouse IgG Subclass Specific Antibodies
Brilliant Violet™ Dye Conjugates for Multiple Labeling
R-PE, APC, PerCP, and other Conjugates for Flow Cytometry
Streptavidin and Conjugates
Anti‑Light Chain-Specific Antibodies for Western Blotting after IP
Alexa Fluor® 680 and Alexa Fluor® 790 for High Sensitivity Western Blots
Cy2, Cy3, and Cy5 for Permanent Mounts
Anti-Fluorescein, Anti-Digoxin, Anti-Biotin, and Anti-HRP
Colloidal Gold-Antibody Complexes
Normal Serums and Gamma Globulins
Bovine Serum Albumin (IgG-Free and Protease-Free)
Purified Proteins from Normal Serum
Antisera
Immunoadsorbent Gels
Peroxidase-Anti-Peroxidase (PAP)
Reporter Enzyme Conjugates For IHC, Western Blot and ELISA
Alpaca Secondary Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Jackson ImmunoResearch Laboratories"> Jackson ImmunoResearch Laboratories
艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物。
笼型倍半硅氧烷,具有无机立方核和外部有机基团的有机-无机杂化化合物。倍半硅氧烷是一种有机硅化合物,其化学式为[RSiO3/2]n(R=H,烷基,芳基或烷氧基)。倍半硅氧烷是无色固体,采用笼状或聚合结构,具有Si-O-Si键和四面体Si顶点。倍半硅氧烷是多八面体倍半硅氧烷(POSS)的一种,作为陶瓷材料和纳米复合材料的前驱体引起了人们的关注。不同的取代基(R)可以连接到Si中心。这些分子是不寻常的,因为它们具有无机硅酸盐核和有机表面。硅芯具有刚性和热稳定性。
Hybrid Plastics致力于提供全球最高质量的POSS®材料。具有ISO 9001:2008的质量管理体系,艾美捷科技有限公司与Hybrid Plastics Inc.长期合作,致力于为中国用户提供:Acrylates-POSS、Alcohols-POSS、Amines-POSS、Carboxylic Acids-POSS、Epoxides-POSS、Fluoroalkyls-POSS、Halides-POSS、Methacrylates-POSS、Molecular Silicas-POSS、Norbornenyls-POSS、Olefins-POSS、PEGs-POSS、Silanes-POSS、Silanols-POSS、Thiols-POSS等化合物。
MA0736 Acryloxypropyl POSS Cage mixture 现货销售 
MA0735 Methacryloxypropyl POSS 现货销售 
AM0270 AminopropylIsooctyl POSS 现货销售 


产品主要包括:
http://www.amyjet.com/Index/lists/catid/27/kid/28.html
<| 货号品名 | 规格 |
| AL0125 – Trans-cyclohexandiol Isobutyl POSS | 1kg |
| AL0130 – 1,2-Propanediolisobutyl POSS | 1kg |
| AM0265 – AminopropylIsobutyl POSS | 100g,500g,1kg |
| AM0270 – AminopropylIsooctyl POSS | 100g,500g,1kg |
| AM0281 (Neat) – N-Phenylaminopropyl POSS | 25g,50g,100g,500g,1kg |
| AM0281.01.30 – N-Phenylaminopropyl POSS | 50g,1kg |
| EP0408.01.30 – Epoxycyclohexyl ethyl POSS cage mixture 30% PGMEA | 100g,1kg |
| EP0409 – Glycidyl POSS cage mixture | 100g,1kg |
| EP0409.07.30 – Glycidyl POSS Nanosilica Dispersion | 1kg |
| EP3530 – POSS Bond EP3530 | 1 Quart, 1 Gallon |
| HC0304.11 Cyclohexylepoxy Glycidyl POSS | |
| HC0310.31 – Cyclohexylethylepoxy isoOctyl POSS | |
| HC0313.31 – Cyclohexylethylepoxy PEG POSS | |
| HC0407.11 – Glycidyl Methacryl POSS | |
| HC0407.13 – Glycidyl Methacryl POSS | |
| HC0407.31 – Glycidyl Methacryl POSS | |
| HC040713.332 Glycidyl Methacryl PEG POSS | |
| HC0413.53 – Glycidyl PEG POSS | |
| HC0507.53 – Trifluoropropyl Methacrylpropyl POSS | |
| HC0613.53 – Acrylic PEG | |
| HC07051013.2211 Methacrylpropyl Trifluoropropyl iso-Octyl PEG POSS | |
| HC0709.13 Methacrylpropyl iso-butyl POSS | |
| HC0710.13 – Methacryloxypropyl isoOctyl POSS | |
| HC0713.31 – Methacryloxypropyl PEG POSS | |
| HC1110.71 Vinyl iso-Octyl POSS | |
| MA0701 – Acryloxypropyl isobutyl POSS | 1kg |
| MA0702 – Methacrylpropyloisobutyl POSS | 1kg |
| MA0719 – Methacryloxypropyl isooctyl POSS | 1kg |
| MA0735 – Methacryloxypropyl POSS | |
| MA0736 – Acryloxypropyl POSS Cage mixture | 100g,1kg |
| MA0735.08.30 – Methacrylic POSS Nanosilica Dispersion | |
| MA0736.08.30 – Acrylic POSS Nanosilica Dispersion | |
| MA0737 – Alpha Methacryl POSS | |
| MS0802 – DodecaPhenyl POSS | 1kg |
| MS0805 – OctaIsooctyl POSS | 1kg |
| MS0825 – OctaIsobutyl POSS | 1kg |
| MS0860 – OctaTMA POSS | 1kg |
| PG1190 – MethoxyPEG POSS cage mixture | 100g,500g,1kg |
| PG1193 HC1013.31 – MethoxyPEGisoOctyl POSS | |
| PM1270 – Phenyl Silanol Resin | 100g |
| SH1310 – Octasilane POSS | 50g |
| SO1450 – Trisilanol isobutyl POSS | 100g,1kg |
| SO1455 – TriSilanollsooctyl POSS | 100g,1kg |
| SO1458 – Trisilanol phenyl POSS | 100g,1kg |
| TH1555 – Mercaptopropyl isooctyl POSS | 50g,100g |
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物"> 艾美捷科技代理Hybrid Plastics全系列倍半硅氧烷POSS化合物

Neuromab是一家由NIH资助成立的单克隆抗体库。
The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
Neuromab的主要产品包括:
Array Tomography
Model Organisms
Disease Targets
产品列表:
| 抗体名称 |
| Anti-5-formylcytidine, NeuroMab clone N358/68 |
| Anti-5-hydroxymethylcytidine, NeuroMab clone N297/59 |
| Anti-6xHis, NeuroMab clone N144/14 |
| Anti-ADAM11, NeuroMab clone N441/35 |
| Anti-ADAM22-cytoplasmic, NeuroMab clone N46/30 |
| Anti-ADAM22-extracellular, NeuroMab clone N57/2 |
| Anti-AGPS neo-epitope, NeuroMab clone N444/63 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/39 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/31 |
| Anti-Alg13, NeuroMab clone N442/28 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/80 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/51 |
| Anti-AMIGO-1, NeuroMab clone L86/33 |
| Anti-AMIGO-1, NeuroMab clone L86/36 |
| Anti-AMIGO-1, NeuroMab clone L86A/37 |
| Anti-Ankyrin-B, NeuroMab clone N105/13 |
| Anti-Ankyrin-B, NeuroMab clone N105/17 |
| Anti-Ankyrin-G, NeuroMab clone N106/20 |
| Anti-Ankyrin-G, NeuroMab clone N106/36 |
| Anti-Ankyrin-G, NeuroMab clone N106/65 |
| Anti-Ankyrin-G, NeuroMab clone N106/43 |
| Anti-Ankyrin-R, NeuroMab clone N388A/10 |
| Anti-Ankyrin-R/G, NeuroMab clone N388A/27 |
| Anti-ANO3/TMEM16C, NeuroMab clone N454/91 |
| Anti-ANO5/TMEM16E, NeuroMab clone N421A/85 |
| Anti-ANO6/TMEM16F, NeuroMab clone N429/19 |
| Anti-ARHGAP4, NeuroMab clone N290B/25 |
| Anti-Arl13b, NeuroMab clone N295B/66 |
| Anti-Arx, NeuroMab clone N411/51 |
| Anti-ASIC1, NeuroMab clone N271/44 |
| Anti-ATAT1, NeuroMab clone N347/42 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/8 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/3 |
| Anti-Ataxin-1 wild-type, NeuroMab clone N65/37 |
| Anti-ATF4, NeuroMab clone N360A/24 |
| Anti-BAF53a, NeuroMab clone N336B/83 |
| Anti-BAF53b, NeuroMab clone N332B/15 |
| Anti-Bassoon, NeuroMab clone L124/59 |
| Anti-BBS3/Arl6, NeuroMab clone N302/10 |
| Anti-BBS5, NeuroMab clone N304B/115 |
| Anti-BDNF, NeuroMab clone N450/53 |
| Anti-Beta1-spectrin, NeuroMab clone N385/21 |
| Anti-Beta4-spectrin, NeuroMab clone N393/2 |
| Anti-Beta4-spectrin, NeuroMab clone N393/76 |
| Anti-BKBeta2 potassium channel subunit, NeuroMab clone N53/32 |
| Anti-BKBeta3a potassium channel subunit, NeuroMab clone N40B/18 |
| Anti-BKBeta4 potassium channel, NeuroMab clone L18A/3 |
| Anti-Botch1/Chac1, NeuroMab clone N116/14 |
| Anti-Bral1, NeuroMab clone N364/10 |
| Anti-Bral1, NeuroMab clone N364/42 |
| Anti-Brevican, NeuroMab clone N294A/6 |
| Anti-Brevican, NeuroMab clone N294A/10 |
| Anti-CALB1/calbindin, NeuroMab clone L109/39 |
| Anti-CALB1/calbindin, NeuroMab clone L109/57 |
| Anti-CALB2/calretinin, NeuroMab clone L122/6 |
| Anti-CALB2/calretinin, NeuroMab clone L122/68 |
| Anti-CASK scaffolding protein, NeuroMab clone K56A/50 |
| Anti-Caspr/paranodin/neurexin IV, NeuroMab clone K65/35 |
| Anti-Caspr2/paranodin, NeuroMab clone K67/25 |
| Anti-Cav1.2 calcium channel, NeuroMab clone L57/46 |
| Anti-Cav1.2, NeuroMab clone N263/31 |
| Anti-Cav1.3 calcium channel, NeuroMab clone L48A/9 |
| Anti-Cav1.3 calcium channel, NeuroMab clone N38/8 |
| Anti-Cav3.1 Ca2+ channel, NeuroMab clone N178A/9 |
| Anti-Cav3.2 calcium channel, NeuroMab clone N55/10 |
| Anti-Cav1 calcium channel, NeuroMab clone N7/18 |
| Anti-Cav尾2 calcium channel subunit, NeuroMab clone N8b/1 |
| Anti-Cav3 calcium channel, NeuroMab clone N473/36 |
| Anti-Cav尾4 calcium channel, NeuroMab clone N10/7 |
| Anti-Cdkl5, NeuroMab clone EA7 |
| Anti-CDY1/2, NeuroMab clone N143/38 |
| Anti-CDY1/2/L1/L2, NeuroMab clone N143/36 |
| Anti-Celf4/Brunol4, NeuroMab clone N446/80 |
| Anti-FOS, NeuroMab clone N486/32 |
| Anti-FOS, NeuroMab clone N486/76 |
| Anti-Clcn3, NeuroMab clone N258/5 |
| Anti-Clcn4, NeuroMab clone N222/6 |
| Anti-Clcn5, NeuroMab clone N406/47 |
| Anti-CLN3, NeuroMab clone N380/87 |
| Anti-CLN6, NeuroMab clone N400/24 |
| Anti-CNGA1/3 cyclic nucleotide-gated channel, NeuroMab clone L36/12 |
| Anti-Collybistin, NeuroMab clone L120/12 |
| Anti-Collybistin, NeuroMab clone L120/30 |
| Anti-Contactin/F3 scaffold protein, NeuroMab clone K73/20 |
| Anti-Copper-transporting ATPase 1, NeuroMab clone L60/4 |
| Anti-Copper-transporting ATPase 2 (Copper pump 2, Wilsons disease-associated protein, NeuroMab clone L62/29 |
| Anti-Co-Rest/RCOR1 Transcriptional Co-Repressor, NeuroMab clone K72/8 |
| Anti-DEPDC5, NeuroMab clone N463/52 |
| Anti-Dicer, NeuroMab clone N167/7 |
| Anti-DLX1 transcription factor, NeuroMab clone L43/40 |
| Anti-DNAH1, NeuroMab clone N251/14 |
| Anti-DNAH7, NeuroMab clone N250/21 |
| Anti-DNAIC1, NeuroMab clone UNC 65.56.18.11 |
| Anti-DNMT3L, NeuroMab clone N117/9 |
| Anti-Doc2b, NeuroMab clone N150/21 |
| Anti-Dopamine D2 receptor, NeuroMab clone N186/29 |
| Anti-Dopamine D3 receptor, NeuroMab clone N331/19 |
| Anti-EAAC1, NeuroMab clone N420/24 |
| Anti-FGF11 (Fibroblast growth factor 11), NeuroMab clone N92/14 |
| Anti-FGF12/FHF1, NeuroMab clone N94/17 |
| Anti-FGF13 (Fibroblast growth factor 13), NeuroMab clone N91/27 |
| Anti-FGF13B/FHF2B, NeuroMab clone N225A/10 |
| Anti-FGF14/FHF4, NeuroMab clone N56/21 |
| Anti-Fig4/Sac3, NeuroMab clone N202/7 |
| Anti-Flrt3, NeuroMab clone N353/13 |
| Anti-Foxi2, NeuroMab clone N349/96 |
| Anti-Foxi3, NeuroMab clone N359/28 |
| Anti-Frataxin, NeuroMab clone N191/7 |
| Anti-GABA-A-R-Alpha1, NeuroMab clone N95/35 |
| Anti-GABA-A-R-Alpha2, NeuroMab clone N399/19 |
| Anti-GABA-A-R-Alpha4, NeuroMab clone N398A/34 |
| Anti-GABA-A-R-Alpha5, NeuroMab clone N415/24 |
| Anti-GABA-A-R-Alpha6, NeuroMab clone N229A/32 |
| Anti-GABA-A-R-Beta1, NeuroMab clone N96/55 |
| Anti-GABA-A-R-Beta2/3, NeuroMab clone 62-3G1 |
| Anti-GABA-A-R-Beta3, NeuroMab clone N87/25 |
| Anti-Delta GABA-A receptor, NeuroMab clone N151/3 |
| Anti-GABA-A-R-Epsilon, NeuroMab clone N413/67 |
| Anti-GABA-A-R-Gamma2L, NeuroMab clone N452/69 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/73 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/30 |
| Anti-GABA-A-R-Pi, NeuroMab clone N431/64 |
| Anti- GABA-A-R-Theta, NeuroMab clone L123/109 |
| Anti-GABABR1 GABA-B receptor, NeuroMab clone N93A/49 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/2 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/37 |
| Anti-GAD65/67, NeuroMab clone L127/12 |
| Anti-GAD67, NeuroMab clone L127/8 |
| Anti-Gamma-protocadherin-A3, NeuroMab clone N144/17 |
| Anti-Gamma-protocadherin-B2, NeuroMab clone N148/30 |
| Anti-Gamma-protocadherin-C3, NeuroMab clone N174B/27 |
| Anti-Gamma-protocadherin-C4, NeuroMab clone N193A/13 |
| Anti-Gephyrin, NeuroMab clone L106/83 |
| Anti-Gephyrin, NeuroMab clone L106/93 |
| Anti-Gephyrin, NeuroMab clone L106/4 |
| Anti-GFAP, NeuroMab clone N206A/8 |
| Anti-GFAP-R416WT, NeuroMab clone N206B/9 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/8 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/38 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/20 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/44 |
| Anti-GIT1 scaffold protein, NeuroMab clone N39B/8 |
| Anti-GIT2 scaffold protein, NeuroMab clone N83/48 |
| Anti-GluA1/GluR1 glutamate receptor, NeuroMab clone N355/1 |
| Anti-GluA2/GluR2 glutamate receptor, NeuroMab clone L21/32 |
| Anti-KA2 kainate receptor, NeuroMab clone N279B/27 |
| Anti-GluN1/NR1 glutamate receptor, NeuroMab clone N308/48 |
| Anti-NR2A glutamate receptor, NeuroMab clone N327A/38 |
| Anti-GluN2A/NR2A glutamate receptor, NeuroMab clone N327/95 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/20 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/36 |
| Anti-GluN2C/NR2C, NeuroMab clone N422/18 |
| Anti- GluN3A/NR3A, NeuroMab clone N416/40 |
| Anti-Glycine receptor Alpha3, NeuroMab clone N424/45 |
| Anti-Glycine receptor Alpha3L, NeuroMab clone N424/48 |
| Anti-GRK6A/B, NeuroMab clone N142/28 |
| Anti-Gs protein alpha subunit, NeuroMab clone N192/12 |
| Anti-GST (Glutathione S-transferase), NeuroMab clone N100/13 |
| Anti-Haspin/GSG2, NeuroMab clone N128A/2 |
| Anti-HCN1 cyclic nucleotide-gated channel, NeuroMab clone N70/28 |
| Anti-HCN2 cyclic nucleotide-gated channel, NeuroMab clone N71/37 |
| Anti-HCN3 cyclic nucleotide-gated channel, NeuroMab clone N141/28 |
| Anti-HCN4 cyclic nucleotide-gated channel, NeuroMab clone N114/10 |
| Anti-Histone H2A.Z/V, NeuroMab clone N310/21 |
| Anti-Histone H2A.Z acetyl-Lys4/7/11, NeuroMab clone N299/39 |
| Anti-Histone H3.3, NeuroMab clone N158/28 |
| Anti-Histone H3 acetyl-Lys56, NeuroMab clone N307/12 |
| Anti-Histone H3-dimethyl-Arg8, NeuroMab clone N293/50 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/19 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/48 |
| Anti-Histone H4-dimethyl-Arg3, NeuroMab clone N309A/21 |
| Anti-Homer1L, NeuroMab clone L113/27 |
| Anti-Homer1L, NeuroMab clone L113/13 |
| Anti-Homer1, NeuroMab clone L113/130 |
| Anti-ICK, NeuroMab clone N451/73 |
| Anti-Iduna/RNF146, NeuroMab clone N201/35 |
| Anti-INPP4b, NeuroMab clone N171/17 |
| Anti IP3 receptor type 1 NeuroMab clone L24/18 |
| Anti-IRSp53/BAIAP2, NeuroMab clone L117/1 |
| Anti-JIP-2/IB-2, NeuroMab clone N135/37 |
| Anti-JMJD2A, NeuroMab clone N154/32 |
| Anti-KCC2 transporter, NeuroMab clone N1/66 |
| Anti-KCC2 transporter, NeuroMab clone N1/12 |
| Anti-KChIP1 potassium channel, NeuroMab clone K55/7 |
| Anti-KChIP2 potassium channel subunit, NeuroMab clone K60/73 |
| Anti-KChIP3 potassium channel, NeuroMab clone K66/38 |
| Anti-KChIP4 K+ channel, NeuroMab clone N423/75 |
| Anti-KCNT1/Slo2.2/Slack K+ channel, NeuroMab clone N3/26 |
| Anti-KCNT2/Slo2.1/Slick sodium- and chloride-activated ATP sensitive potassium channel, NeuroMab clone N11/33 |
| Anti-KCNU1/Slo3 pH-sensitive maxi potassium channel, NeuroMab clone N2/16 |
| Anti-Keyhole limpet hemocyanin, NeuroMab clone N132A/12 |
| Anti-Kir2.1 potassium channel, NeuroMab clone N112B/14 |
| Anti-Kir2.2 potassium channel, NeuroMab clone N124B/38 |
| Anti-Kir2.3 potassium channel, NeuroMab clone N25/35 |
| Anti-Kir2.4 potassium channel, NeuroMab clone N465/11 |
| Anti-Kir3.3 potassium channel, NeuroMab clone N455/15 |
| Anti-Kir6.1 potassium channel, NeuroMab clone N366/60 |
| Anti-Kir6.2 potassium channel, NeuroMab clone N363/71 |
| Anti-Kirrel3 short and long, NeuroMab clone N321C/49 |
| Anti-Kirrel3 short isoform 3, NeuroMab clone N320/48 |
| Anti-Kv1.1 potassium channel subunit, NeuroMab clone K20/78 |
| Anti-Kv1.1 potassium channel (external), NeuroMab clone K36/15 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K14/16 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone L76/36 |
| Anti-Kv1.3 potassium channel, NeuroMab clone L23/27 |
| Anti-Kv1.4 potassium channel subunit, NeuroMab clone K13/31 |
| Anti-Kv1.4 potassium channel (extracellular), NeuroMab clone L71/5 |
| Anti-Kv1.5 potassium channel, NeuroMab clone K7/45 |
| Anti-Kv1.6 potassium channel subunit, NeuroMab clone K19/36 |
| Anti-Kv1.7 potassium channel, NeuroMab clone N471/27 |
| Anti-Kv11.3 potassium channel, NeuroMab clone N447/24 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L83/11 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone K89/34 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L80/21 |
| Anti-Kv2.1 potassium channel (external), NeuroMab clone K39/25 |
| Anti-Kv2.2 potassium channel, NeuroMab clone K37/89 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372C/51 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/60 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/1 |
| Anti-Kv3.1b potassium channel, NeuroMab clone N16b/8 |
| Anti-Kv3.2 potassium channel, NeuroMab clone N410/17 |
| Anti-Kv3.3 potassium channel, NeuroMab clone N375/67 |
| Anti-Kv3.4 potassium channel, NeuroMab clone N72/16 |
| Anti-Kv4.2 potassium channel subunit, NeuroMab clone L28/4 |
| Anti-Kv4.2 potassium channel (external), NeuroMab clone K57/1 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/41 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/30 |
| Anti-Kv6.1 potassium channel, NeuroMab clone N474/27 |
| Anti-Kv6.4 potassium channel, NeuroMab clone N458/10 |
| Anti-KCNQ1 potassium channel, NeuroMab clone N37A/10 |
| Anti-KCNQ2 potassium channel, NeuroMab clone N26A/23 |
| Anti-KCNQ4 potassium channel, NeuroMab clone N43/6 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/88 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/50 |
| Anti-Kv9.1 potassium channel, NeuroMab clone N461/19 |
| Anti-Kv9.2 potassium channel, NeuroMab clone N460/19 |
| Anti-Kvβ1.1 potassium channel subunit, NeuroMab clone K9/40 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K47/42 |
| Anti-Kv尾2 potassium channel, NeuroMab clone K17/70 |
| Anti-Laforin, NeuroMab clone N84/37 |
| Anti-LAR/PTPRF, NeuroMab clone N165/38 |
| Anti-Lgi1, NeuroMab clone N283/7 |
| Anti-Lhx6.1, NeuroMab clone N228A/16 |
| Anti-LRP4 (cytoplasmic), NeuroMab clone N164/6 |
| Anti-LRP4 (extracellular), NeuroMab clone N207/27 |
| Anti-LRRK1, NeuroMab clone N341/37 |
| Anti-LRRK1, NeuroMab clone N341/12 |
| Anti-LRRK2/Dardarin, NeuroMab clone N241A/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone N231B/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone 8G10 |
| Anti-LRRK2/Dardarin, NeuroMab clone N138/6 |
| Anti-LRRK2/Dardarin-pSer910, NeuroMab clone 1D8 |
| Anti-LRRTM2, NeuroMab clone N209C/35 |
| Anti-LRRTM4, NeuroMab clone N205B/22 |
| Anti-Mad3, NeuroMab clone N129A/6 |
| Anti-Mad3, NeuroMab clone N129/15 |
| Anti-Malin, NeuroMab clone N85/18 |
| Anti-MBP (Maltose-binding protein), NeuroMab clone N128A/4 |
| Anti-MAP3K12, NeuroMab clone N377/20 |
| Anti-MAP3K12, NeuroMab clone N377/83 |
| Anti-MECP2, NeuroMab clone N227/21 |
| Anti-MESD, NeuroMab clone N88/12 |
| Anti-MFF, NeuroMab clone N382/14 |
| Anti-MFF (exon 1), NeuroMab clone N382/69 |
| Anti-MGL, NeuroMab clone N90/20 |
| Anti-mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/3 |
| Anti- mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/33 |
| Anti-Miro2, NeuroMab clone N384/63 |
| Anti-MiRP4 potassium channel, NeuroMab clone N472/88 |
| Anti-Mitofusin-1 (Mfn1), NeuroMab clone N111/24 |
| Anti-Mitofusin-2 (Mfn2), NeuroMab clone N153/5 |
| Anti-MMACHC, NeuroMab clone N230/21 |
| Anti-MMP9 metalloproteinase, NeuroMab clone L51/82 |
| Anti-MOG, NeuroMab clone L94/54 |
| Anti-Mortalin/GRP75, NeuroMab clone N52A/42 |
| Anti-MPP8, NeuroMab clone N119/44 |
| Anti-NALCN, NeuroMab clone N185/7 |
| Anti-Nav1.1 sodium channel, NeuroMab clone K74/71 |
| Anti-Nav1.2 sodium channel, NeuroMab clone K69/3 |
| Anti-Nav1.4 sodium channel, NeuroMab clone N255/38 |
| Anti-Nav1.5 sodium channel, NeuroMab clone N397/19 |
| Anti-Nav1.6 sodium channel, NeuroMab clone K87A/10 |
| Anti-Nav1.7 sodium channel, NeuroMab clone N68/6 |
| Anti-Nav1.8 sodium channel, NeuroMab clone N134/12 |
| Anti-Navbeta1 Na+ channel, NeuroMab clone N405/74 |
| Anti-Navbeta2 Na+ channel, NeuroMab clone N395/68 |
| Anti-Navbeta3 Na+ channel, NeuroMab clone N396/29 |
| Anti-Navbeta4 sodium channel, NeuroMab clone N168/6 |
| Anti-NCKX4, NeuroMab clone N414/25 |
| Anti-Neuregulin-CRD (Cysteine-rich domain, Type III), NeuroMab clone N126B/31 |
| Anti-Neuregulin-HBD (Heparin-binding domain, Type I/II), NeuroMab clone N120A/9 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/1 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/26 |
| Anti-Neuroligin-1, NeuroMab clone N97A/31 |
| Anti-Neuroligin-2, NeuroMab clone L107/39 |
| Anti-Neuroligin-3, NeuroMab clone N110/29 |
| Anti-Neuroligin-4*, NeuroMab clone N98/47 |
| Anti-Neuroligin-4*, NeuroMab clone N98/7 |
| Anti-NGL-1 (Netrin-G1 ligand), NeuroMab clone N49A/21 |
| Anti-NGL-2 (Netrin-G2 ligand) NeuroMab clone N50/36 |
| Anti-NGL-3 (Netrin-G3 ligand), NeuroMab clone N51/6 |
| Anti-NKCC1, NeuroMab clone N161/20 |
| Anti-NOS1/nNOS, NeuroMab clone L121/25 |
| Anti-NOS1/nNOS, NeuroMab clone L121/42 |
| Anti-Notch1, NeuroMab clone N253/32 |
| Anti-Npas4, NeuroMab clone N408/62 |
| Anti-Npas4, NeuroMab clone N408/79 |
| Anti-Neuropeptide Y, NeuroMab clone L115/13 |
| Anti-NPY2R, NeuroMab clone L119/106 |
| Anti-NrCAM, NeuroMab clone N343/26 |
| Anti-NSD1, NeuroMab clone N312/10 |
| Anti-NSD3, NeuroMab clone N348/82 |
| Anti-OCRL/INPP5b, NeuroMab clone N166A/26 |
| Anti-Olig1, NeuroMab clone N149/25 |
| Anti-Pan-Ankyrin, NeuroMab clone N388A/60 |
| Anti-Pancortin, NeuroMab clone K96/7 |
| Anti-Pan-FHF-A, NeuroMab clone N235/22 |
| Anti-Pan-Gamma-protocadherin-A, NeuroMab clone N144/32 |
| Anti-Pan-Gamma-protocadherin, NeuroMab clone N159/5 |
| Anti-Pan-GRK, NeuroMab clone N145/20 |
| Anti-Pan-KChIP potassium channel, NeuroMab clone K55/82 |
| Anti-Pan-Kv potassium channel, NeuroMab clone K40/17 |
| Anti-Pan-Kvbeta potassium channel, NeuroMab clone K25/73 |
| Anti-Pan-MAGUK scaffold proteins, NeuroMab clone K28/86 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/40 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/78 |
| Anti-pan-Neurofascin, NeuroMab clone L11A/41 |
| Anti-Pan-Neurofascin (external), NeuroMab clone A12/18 |
| Anti-Pannexin-2, NeuroMab clone N121A/1 |
| Anti-Pannexin-2, NeuroMab clone N121A/31 |
| Anti-Pan-PTPR, NeuroMab clone N165/43 |
| Anti-Pan-QKI, NeuroMab clone N147/6 |
| Anti-Pan-SAPAP, NeuroMab clone N127/31 |
| Anti-pan-Shank (SH3 and multiple ankyrin repeat domains protein) scaffold protein, NeuroMab clone N23B/49 |
| Anti-Pan-Synapsin, NeuroMab clone L125/129 |
| Anti-Pan-Thyroid hormone receptor, NeuroMab clone N403/63 |
| Anti-PARIS/ZNF746, NeuroMab clone N196/16 |
| Anti-Parvalbumin, NeuroMab clone L114/3 |
| Anti-Parvalbumin, NeuroMab clone L114/81 |
| Anti-PEX6, NeuroMab clone N233/8 |
| Anti-PEX7, NeuroMab clone N232/9 |
| Anti-Phosphoserine-2-OEt, NeuroMab clone N257/25 |
| Anti-Phosphoserine-2-OH, NeuroMab clone N259/48 |
| Anti-Phosphoserine-2-OMe, NeuroMab clone N262/16 |
| Anti-PhyH/PAHX, NeuroMab clone N210/5 |
| Anti-PICK1 scaffold, NeuroMab clone L20/8 |
| Anti-PINK1, NeuroMab clone N4/15 |
| Anti-PINK1, NeuroMab clone N4/49 |
| Anti-PINK1, NeuroMab clone N4/19 |
| Anti-PINK1, NeuroMab clone N357/6 |
| Anti-Proser1, NeuroMab clone N456/39 |
| Anti-Prrt2, NeuroMab clone N485/22 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/30 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/28 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/43 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/74 |
| Anti-QKI-5-NLS, NeuroMab clone N195A/16 |
| Anti-QKI-6, NeuroMab clone N182/17 |
| Anti-QKI-7, NeuroMab clone N183/15 |
| Anti-QKI-7b, NeuroMab clone N194/11 |
| Anti-RBM17/SPF45, NeuroMab clone N219/5 |
| Anti-REEP, NeuroMab clone N326D/13 |
| Anti-REEP1, NeuroMab clone N345/51 |
| Anti-REEP1/2, NeuroMab clone N326D/29 |
| Anti-REEP2, NeuroMab clone N326D/2 |
| Anti-Rem2, NeuroMab clone N324/2 |
| Anti-RGS14, NeuroMab clone N133/21 |
| Anti-RGS14, NeuroMab clone N133/35 |
| Anti-Rufy3, NeuroMab clone N483/84 |
| Anti-Rufy3, NeuroMab clone N483/126 |
| Anti-Rufy3, NeuroMab clone N483/26 |
| Anti-S100A5, NeuroMab clone N176A/35 |
| Anti-SALM2 synaptic adhesion-like molecule, NeuroMab clone N52B/27 |
| Anti-SALM5/LRFN5, NeuroMab clone N140A/12 |
| Anti-SAP102 MAGUK scaffold protein, NeuroMab clone N19/2 |
| Anti-SAP97 scaffold protein, NeuroMab clone K64/15 |
| Anti-SAPAP1, NeuroMab clone N238/29 |
| Anti-SAPAP1, NeuroMab clone N238/30 |
| Anti-SAPAP1/2, NeuroMab clone N238/31 |
| Anti-SAPAP2, NeuroMab clone N459/84 |
| Anti-SAPAP3, NeuroMab clone L126/93 |
| Anti-SCG10/stathmin-2, NeuroMab clone L5/1 |
| Anti-SH3GL1, NeuroMab clone K51/1 |
| Anti-Shank1/ SPANK-1/Synamon/SSTRIP scaffold protein, NeuroMab clone N22/21 |
| Anti-Shank1 and Shank3, NeuroMab clone N367/51 |
| Anti-Shank2/ProSAP1/Spank-3/CortBP1 scaffold protein,NeuroMab clone N23B/6 |
| Anti-Shank3 scaffold protein, NeuroMab clone N69/46 |
| Anti-Shank3, NeuroMab clone N367/62 |
| Anti-SK2 potassium channel, NeuroMab clone K78/29 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/23 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/48 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/60 |
| Anti-Snapin (SNAP25 binding protein), NeuroMab clone L8/15 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/37 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/32 |
| Anti-SST/Somatostatin, NeuroMab clone L111/118 |
| Anti-S-tag, NeuroMab clone N56/9 |
| Anti-Stonin-2, NeuroMab clone N346/9 |
| Anti-SUR1, NeuroMab clone N289/16 |
| Anti-SUR1 and SUR2B, NeuroMab clone N323A/31 |
| Anti-SUR2A, NeuroMab clone N319A/14 |
| Anti-SUR2B, NeuroMab clone N323B/20 |
| Anti-SVOP, NeuroMab clone N356/9 |
| Anti-SVOP, NeuroMab clone N356/23 |
| Anti-Synapsin-III, NeuroMab clone L125/121 |
| Anti-Synaptotagmin-10, NeuroMab clone N269/73 |
| Anti-Synaptotagmin-12, NeuroMab clone N277/7 |
| Anti-Synaptotagmin-3, NeuroMab clone N278/19 |
| Anti-Synaptotagmin-5, NeuroMab clone N274/8 |
| Anti-Synaptotagmin-6, NeuroMab clone N270/47 |
| Anti-Synaptotagmin-7, NeuroMab clone N275/14 |
| Anti-Synaptotagmin-9, NeuroMab clone N276A/15 |
| Anti-SynCAM1 cell adhesion molecule, NeuroMab clone L45/30 |
| Anti-SynCAM4, NeuroMab clone N244/5 |
| Anti-SynDIG1/Tmem90b, NeuroMab clone L42/17 |
| Anti-SynDIG3/Tmem91, NeuroMab clone N160/21 |
| Anti-SynDIG4, NeuroMab clone L102/45 |
| Anti-Tafazzin, NeuroMab clone N173B/13 |
| Anti-TALK1 potassium channel, NeuroMab clone N466/14 |
| Anti-TARPGamma2/Stargazin, NeuroMab clone N245/1 |
| Anti-TARPGamma2/4/8, NeuroMab clone N245/36 |
| Anti-TASK1 potassium channel, NeuroMab clone N374/48 |
| Anti-Tauro-GM2, NeuroMab clone N175/9 |
| Anti-THAP1, NeuroMab clone N325B/65 |
| Anti-THIK-2 potassium channel, NeuroMab clone N468/37 |
| Anti-Thioredoxin, NeuroMab clone N245/44 |
| Anti-Thorase (Atad1), NeuroMab clone N125/10 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/13 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/46 |
| Anti- TRAAK potassium channel, NeuroMab clone N445/27 |
| Anti-TRAK1, NeuroMab clone N389/9 |
| Anti-TRAK2, NeuroMab clone N390/43 |
| Anti-TRESK potassium channel, NeuroMab clone N467/1 |
| Anti-TRIP8b (constant), NeuroMab clone N212/7 |
| Anti-TRIP8b (constant), NeuroMab clone N212/17 |
| Anti-TRIP8b (exon 1a/5 junction), NeuroMab clone N291C/22 |
| Anti-TRIP8b (exon 1b), NeuroMab clone N212A/34 |
| Anti-TRIP8b (exon 4), NeuroMab clone N212/3 |
| Anti-TrpC1 calcium channel, NeuroMab clone 1F1 |
| Anti-TrpC4 calcium channel, NeuroMab clone N77/15 |
| Anti-TrpC5 calcium channel, NeuroMab clone N67/15 |
| Anti-TrpC7 calcium channel, NeuroMab clone N64A/36 |
| Anti-TrpM4, NeuroMab clone L88/86 |
| Anti-TrpM6, NeuroMab clone N470/22 |
| Anti-TrpM7 ion channel and Ser/Thr kinase, NeuroMab clone N74/25 |
| Anti-TRPML3/Mucolipin-3, NeuroMab clone N268/19 |
| Anti-TrpV1, NeuroMab clone N221/17 |
| Anti-TrpV1, NeuroMab clone N221/12 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/4 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/39 |
| Anti-TWIK-2 potassium channel, NeuroMab clone N469/28 |
| Anti-Uncx, NeuroMab clone N155/9 |
| Anti-VAChT vesicular acetylcholine transporter, NeuroMab clone N6/38 |
| Anti-VAChT, NeuroMab clone N425/45 |
| Anti-VAPA, NeuroMab clone N479/12 |
| Anti-VAPA, NeuroMab clone N479/22 |
| Anti-VAPA/B, NeuroMab clone N479/107 |
| Anti-VDAC1, NeuroMab clone N152B/23 |
| Anti-Versican, NeuroMab clone N351/23 |
| Anti-Versican, NeuroMab clone N351/24 |
| Anti-VGAT, NeuroMab clone L118/80 |
| Anti-VGAT, NeuroMab clone L118/66 |
| Anti-VGlut1, NeuroMab clone N28/9 |
| Anti-VGlut2, NeuroMab clone N29/29 |
| Anti-VGlut3, NeuroMab clone N34/34 |
| Anti-VIP, NeuroMab clone L108/92 |
| Anti-VMAT1, NeuroMab clone N440/21 |
| Anti-VMAT1, NeuroMab clone N440/61 |
| Anti-Slc18a2/VMAT2, NeuroMab clone N449/73 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/21 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/63 |
| Anti-WAVE1/SCAR, NeuroMab clone K91/36 |
| Anti-WNK1, NeuroMab clone N391/68 |
| Anti-WRN, NeuroMab clone N428/12 |
| Zebrafish PSD Marker, NeuroMab clone N286/74 |
| Anti-Zinedin/Striatin-4, NeuroMab clone K88/64 |
| Anti-ZIP3, NeuroMab clone N476/9 |
| Anti-ZNF423, NeuroMab clone N328B/37 |

艾美捷科技代理rPeptide品牌全系列重组蛋白及多肽产品。
rPeptide公司提供高质量的肽、试剂、蛋白质、抗体等,专注于老年痴呆症和帕金森病的研究。rPeptide专有的平台载体技术能够在大肠杆菌中以可溶性肽/蛋白质的形式重组表达困难的肽/蛋白质。rPeptide还提供大量的β-淀粉样蛋白、taus、突触核蛋白、钙调素、定制产品等。
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
rPeptide产品详情请见艾美捷科技丁香通商城:
https://vicbio.biomart.cn/supply/c_282851.htm
<| Beta Amyloid 7E7 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-1101-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-1101-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-1101-4 | 1.0mg |
| Beta Amyloid 7E7 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-1102-1 | 50ug |
| Beta Amyloid 7E7 100ug and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-2 | 100ug |
| Beta Amyloid 7E7 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-1102-3 | 0.5mg |
| Beta Amyloid 7E7 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-1102-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-40)NH4OH .25mg | BA-2201-1 | 50ug |
| Beta Amyloid 6C2 100ug and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-40)NH4OH .5mg | BA-2201-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-40)NH4OH 1.0mg | BA-2201-4 | 1.0mg |
| Beta Amyloid 6C2 50ug and Beta Amyloid (1-42)NH4OH .25mg | BA-2202-1 | 50ug |
| Beta-Amyloid 6C2, 100ug and Beta Amyloid (1-42) NH4OH 0.5mg | BA-2202-2 | 100ug |
| Beta Amyloid 6C2 .5mg and Beta Amyloid (1-42)NH4OH .5mg | BA-2202-3 | 0.5mg |
| Beta Amyloid 6C2 1.0mg and Beta Amyloid (1-42)NH4OH 1.0mg | BA-2202-4 | 1.0mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-02 | 1 x .25mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-1 | 1 x 0.5mg |
| Beta Amyloid (1-40) Aggregation Kit | A-1180-2 | 1 x 1.0mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-02 | 1 x .25 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-1 | 1 x 0.5 mg |
| Beta Amyloid (1-42) Aggregation Kit | A-1170-2 | 1 x 1.0 mg |
| Beta-Amyloid (1-40), Mouse, Rat | A-1007-1 | 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-1 | 5 x 0.5 mg |
| Beta-Amyloid (1-40), Starter Kit | A-1150-2 | 5 x 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HCl | A-1156-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, HFIP | A-1153-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, NaOH | A-1155-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra Pure, TFA | A-1001-2 | 1.0 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-02 | 250 ug |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-1 | 0.5 mg |
| Beta-Amyloid (1-40), Ultra-Pure, Ammonium Hydroxide | A-1157-2 | 1 mg |
| Beta-Amyloid (1-40, D23N) | A-1013-1 | 100 µg |
| Beta-Amyloid (1-40, D23N) | A-1013-2 | 1.0 mg |
| Beta-Amyloid (1-40, F4W) | A-1011-1 | 100 µg |
| Beta-Amyloid (1-11) | A-1051-1 | 1.0 mg |
| Beta-Amyloid (1-11) | A-1051-2 | 5.0 mg |
| Beta-Amyloid (1-16) | A-1052-1 | 1.0 mg |
| Beta-Amyloid (1-16) | A-1052-2 | 5.0 mg |
| Beta-Amyloid (1-28) | A-1053-1 | 0.5 mg |
| Beta-Amyloid (1-28) | A-1053-2 | 1.0 mg |
| Beta-Amyloid (1-38) | A-1078-1 | 0.5 mg |
| Beta-Amyloid (1-38) | A-1078-2 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-1 | 1.0 mg |
| Beta-Amyloid (11-22) | A-1055-2 | 5.0 mg |
| Beta-Amyloid (11-40) | A-1061-2 | 1.0 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-01 | 0.1 mg |
| Beta-Amyloid (11-40), Mouse, Rat | A-1062-1 | 0.5 mg |
| Beta-Amyloid (11-42) | A-1063-2 | 1.0 mg |
| Beta-Amyloid (12-28) | A-1056-1 | 0.5 mg |
| Beta-Amyloid (12-28) | A-1056-2 | 1.0 mg |
| Beta-Amyloid (17-40) | A-1057-1 | 0.5 mg |
| Beta-Amyloid (17-40) | A-1057-2 | 1.0 mg |
| Beta-Amyloid (17-42) | A-1058-1 | 0.5 mg |
| Beta-Amyloid (17-42) | A-1058-2 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-1 | 1.0 mg |
| Beta-Amyloid (22-35) | A-1059-2 | 5.0 mg |
| Beta-Amyloid (25-35) | A-1060-1 | 1.0 mg |
| Beta-Amyloid (25-35) | A-1060-2 | 5.0 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-1 | 0.5 mg |
| 13C Beta-Amyloid (1-40), Uniformly labeled | A-1105-2 | 1.0 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-1 | 0.5 mg |
| 13C Beta-Amyloid (1-42), Uniformly labeled | A-1106-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-01 | 0.1 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-40), Uniformly labeled | A-1103-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-42), Uniformly labeled | A-1104-2 | 1.0 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-1 | 0.5 mg |
| 13C, 15N Beta-Amyloid (1-43), Uniformly labeled | A-1108-2 | 1.0 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-1 | 0.5 mg |
| 13C, Beta-Amyloid (1-43), Uniformly labeled | A-1109-2 | 1.0 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-1 | 0.1 mg |
| 15N Beta-Amyloid (1-38), U. label | A-1147-2 | 1.0 mg |
| 15N Beta-Amyloid (1-40), Rat, U. labeled | A-1131-1 | 0.5 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-1 | 0.1 mg |
| 15N Beta-Amyloid (1-40), Uniformly labeled | A-1101-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Rat, U. labeled | A-1134-2 | 1.0 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-1 | 0.1 mg |
| 15N Beta-Amyloid (1-42), Uniformly labeled | A-1102-2 | 1.0 mg |
| 15N Beta-Amyloid (1-43), Uniformly labeled | A-1107-1 | 1.0 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-1 | 0.1 mg |
| 15N Beta-Amyloid (1-46), U. label | A-1179-2 | 0.5 mg |
| 15N Beta-Amyloid (11-40), Rat, U. label | A-1140-1 | 1.0 mg |
| 15N Beta-Amyloid (11-40), Uniformly labeled | A-1137-1 | 1.0 mg |
| 15N Beta-Amyloid (11-42), U. label | A-1120-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-01 | 0.1 mg |
| Biotin-Beta-Amyloid (1-40) | A-1111-2 | 1.0 mg |
| Biotin-Beta-Amyloid (1-42) | A-1117-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-1 | 0.5 mg |
| Biotin-LC-Beta-Amyloid (1-40) | A-1112-2 | 1.0 mg |
| Biotin-LC-Beta-Amyloid (1-42) | A-1118-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-40) | A-1113-1 | 0.5 mg |
| Fluorescein-Beta-Amyloid (1-42) | A-1119-1 | 0.5 mg |
| Calmodulin, Porcine, Biotinylated | C-1002-1 | 100 µg |
| Calmodulin, Porcine, Fluorescein | C-1003-1 | 100 µg |
| Calmodulin, Porcine, Rhodamine | C-1004-1 | 100 µg |
| Calmodulin, Wheat (Triticum aestivum), Biotinylated | C-1008-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Fluorescein | C-1009-1 | 50 µg |
| Calmodulin, Wheat (Triticum aestivum), Rhodamine | C-1010-1 | 50 µg |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-1 | 50ug |
| 15N Tau-441 (2N4R) Uniform Labeled | T-1101-2 | 100ug |
| Tau Protein Ladder, of all 6 isoforms | T-1007-1 | 50 µl |
| Tau Protein Ladder, of all 6 isoforms | T-1007-2 | 100 µl |
| Tau Starter Kit | T-1170-1 | 50 µg |
| Tau Starter Kit | T-1170-2 | 100 µg |
| Tau-352, (0N3R) | T-1006-1 | 50 µg |
| Tau-352, (0N3R) | T-1006-2 | 100 µg |
| Tau-381, (1N3R) | T-1004-1 | 50 µg |
| Tau-381, (1N3R) | T-1004-2 | 100 µg |
| Tau-383, (0N4R) | T-1005-1 | 50 µg |
| Tau-383, (0N4R) | T-1005-2 | 100 µg |
| Tau-410, (2N3R) | T-1002-1 | 50 µg |
| Tau-410, (2N3R) | T-1002-2 | 100 µg |
| Tau-412, (1N4R) | T-1003-1 | 50 µg |
| Tau-412, (1N4R) | T-1003-2 | 100 µg |
| Tau-441, (2N4R) | T-1001-1 | 50 µg |
| Tau-441, (2N4R) | T-1001-2 | 100 µg |
| Tau-441, (2N4R), G272V mutant | T-1013-1 | 50 µg |
| Tau-441, (2N4R), P301L mutant | T-1014-1 | 50 µg |
| Tau-441, (2N4R), R406W mutant | T-1011-1 | 50 µg |
| Tau-441, (2N4R), V248L mutant | T-1015-1 | 50 µg |
| Tau-441, (2N4R), V337M mutant | T-1012-1 | 50 µg |
| Tubulin, Porcine | T-1201-1 | 1.0 mg |
| Latherin | L-1001-1 | 50ug |
| Latherin | L-1001-2 | 100ug |
| Latherin | L-1001-3 | 0.5mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-1 | 0.5 mg |
| 15N, Alpha-Synuclein, Uniform Label | S-1004-2 | 1.0 mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-1 | .5mg |
| 15N, Beta-Synuclein, Uniform Label | S-1102-2 | 1.0mg |
| Alpha Synuclein Mouse | S-1010-1 | 0.5mg |
| Alpha Synuclein Mouse | S-1010-2 | 1.0mg |
| Alpha-Synuclein | S-1001-1 | 0.5 mg |
| Alpha-Synuclein | S-1001-2 | 1.0 mg |
| Alpha-Synuclein, 1-60 | S-1011-1 | 0.5 mg |
| Alpha-Synuclein, 1-95 | S-1012-1 | 0.5 mg |
| Alpha-Synuclein, 112 (NACP 112) | S-1016-1 | 0.5 mg |
| Alpha-Synuclein, 61-140 | S-1013-1 | 0.5 mg |
| Alpha-Synuclein, 96-140 | S-1014-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-1 | 0.5 mg |
| Alpha-Synuclein, A30P mutant | S-1005-2 | 1.0 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-1 | 0.5 mg |
| Alpha-Synuclein, A30P, A53T mutant | S-1006-2 | 1.0 mg |
| Alpha-Synuclein, A53T mutant | S-1002-1 | 0.5 mg |
| Alpha-Synuclein, A53T mutant | S-1002-2 | 1.0 mg |
| Alpha-Synuclein, Delta NAC | S-1015-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-1 | 0.5 mg |
| Alpha-Synuclein, E46K mutant | S-1008-2 | 1.0 mg |
| Beta-Synuclein | S-1003-1 | 0.5 mg |
| Beta-Synuclein | S-1003-2 | 1.0 mg |
| Gamma-Synuclein | S-1007-1 | 0.5 mg |
| Gamma-Synuclein | S-1007-2 | 1.0 mg |
| Gamma-Synuclein, Mouse | S-1009-1 | 0.5 mg |
| Gamma-Synuclein, Mouse | S-1009-2 | 1.0 mg |
| APP 669-711, HCl | AP-1156-1 | 0.5mg |
| APP 669-711, HCl | AP-1156-2 | 1.0mg |
| APP 669-711, HFIP | AP-1153-1 | 0.5mg |
| APP 669-711, HFIP | AP-1153-2 | 1.0mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-1 | 0.5mg |
| APP 669-711, N15 Uniformly Labelled | AP-1101-2 | 1.0mg |
| APP 669-711, NaOH | AP-1155-1 | 0.5mg |
| APP 669-711, NaOH | AP-1155-2 | 1.0mg |
| APP 669-711, NH4OH | AP-1157-1 | 0.5mg |
| APP 669-711, NH4OH | AP-1157-2 | 1.0mg |
| APP 669-711, TFA | AP-1001-1 | 0.5mg |
| APP 669-711, TFA | AP-1001-2 | 1.0mg |
| Apolipoprotein E, Human Plasma, VLDL | A-2001-1 | 50 µg |
| Alpha 1 Antichymotrypsin | A-2002-1 | 100 µg |
| Alpha 1 Antitrypsin | A-2003-1 | 1.0 mg |
| Alpha 2 Macroglobulin | A-2004-1 | 1.0 mg |
| Chymotrypsin | A-2005-1 | 100 µg |
| Haptoglobin | A-2006-1 | 1.0 mg |
| Myeloperoxidase | A-2007-1 | 100 µg |
| Plasmin | A-2008-1 | 1.0 mg |
| Plasminogen | A-2009-1 | 1.0 mg |
| Transferrin | A-2010-1 | 100 mg |
| Calmodulin, Porcine | C-1001-1 | 1 mg |
| Calmodulin, Wheat (Triticum aestivum) & Porcine | C-1006-1 | 200 µl |
| Calmodulin-SH, Wheat (Triticum aestivum) | C-1007-1 | 250 µg |
| Calmodulin-SH, Wheat (Triticum aestivum), Immobilized | C-1011-1 | 200 µl |
| Alpha Synuclein 10C3 Antibody | SA-3001-1 | 100ug |
| Alpha Synuclein 10C3 Antibody | SA-3001-2 | 1mg |
| Alpha Synuclein 10D2 Antibody | SA-3003-1 | 100ug |
| Alpha Synuclein 10D2 Antibody | SA-3003-2 | 1mg |
| Alpha Synuclein 5G4 Antibody | SA-3002-1 | 100ug |
| Alpha Synuclein 5G4 Antibody | SA-3002-2 | 1mg |
| Alpha Synuclein pAB 63 Antibody | SA-3004-1 | 100ul |
| Alpha Synuclein pAB 63 Antibody | SA-3004-2 | 1ml |
| Tau 3G3 | TA-3012-1 | 100ug |
| Tau 3G3 | TA-3012-2 | 1 mg |
| Tau 4C10 | TA-3011-1 | 100ug |
| Tau 4C10 | TA-3011-2 | 1mg |
| Tau 9D8 Antibody | TA-3010-1 | 100ug |
| Tau 9D8 Antibody | TA-3010-2 | 1mg |
| Tau total 12C2 | TA-3015-1 | 100ug |
| Tau total 12C2 | TA-3015-2 | 1mg |
| Tau total 18B5 | TA-3016-1 | 100ug |
| Tau total 18B5 | TA-3016-2 | 1 mg |
| Tau total 4B5 | TA-3013-1 | 100ug |
| Tau total 4B5 | TA-3013-2 | 1mg |
| Tau total 7E5 | TA-3017-1 | 100ug |
| Tau total 7E5 | TA-3017-2 | 1mg |
| Tau total 8F10 | TA-3014-1 | 100ug |
| Tau total 8F10 | TA-3014-2 | 1 mg |
| Tau total pAB 64 | TA-3020-1 | 100ul |
| Tau total pAB 64 | TA-3020-2 | 1 mg |
| Tau-10D3 Antibody | TA-3004-1 | 100ug |
| Tau-10D3 Antibody | TA-3004-2 | 1mg |
| Tau-10F8 Antibody | TA-3007-1 | 100ug |
| Tau-10F8 Antibody | TA-3007-2 | 1mg |
| Tau-1A6 Antibody | TA-2001-1 | 50ug |
| Tau-1A6 Antibody | TA-2001-2 | 100ug |
| Tau-1A6 Antibody | TA-2001-3 | 1.0mg |
| Tau-1A6 Antibody Kit | TA-1101-1 | 50ug |
| Tau-1A6 Antibody Kit | TA-1101-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2002 | TA-1102-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2004 | TA-1104-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2005 | TA-1105-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2006 | TA-1106-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2007 | TA-1107-2 | 100ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-1 | 50ug |
| Tau-1A6 Antibody Kit TA-2008 | TA-1108-2 | 100ug |
| Tau-1E7 Antibody | TA-3001-1 | 100ug |
| Tau-1E7 Antibody | TA-3001-2 | 1mg |
| Tau-1F3 Antibody | TA-3005-1 | 100ug |
| Tau-1F3 Antibody | TA-3005-2 | 1mg |
| Tau-2B11 Antibody | TA-3008-1 | 100ug |
| Tau-2B11 Antibody | TA-3008-2 | 1mg |
| Tau-4G11 Antibody | TA-1001-1 | 50ug |
| Tau-4G11 Antibody | TA-1001-2 | 100ug |
| Tau-4G11 Antibody | TA-1001-3 | 1.0mg |
| Tau-4G11 Antibody Kit | TA-1111-1 | 50ug |
| Tau-4G11 Antibody Kit | TA-1111-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1003 | TA-1113-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1004 | TA-1114-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1005 | TA-1115-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1006 | TA-1116-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1007 | TA-1117-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1008 | TA-1118-2 | 100ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-1 | 50ug |
| Tau-4G11 Antibody Kit TA-1009 | TA-1119-2 | 100ug |
| Tau-5G7 Antibody | TA-3009-1 | 100ug |
| Tau-5G7 Antibody | TA-3009-2 | 1mg |
| Tau-8B11 Antibody | TA-3002-1 | 100ug |
| Tau-8B11 Antibody | TA-3002-2 | 1mg |
| Tau-8D2 Antibody | TA-3003-1 | 100ug |
| Tau-8D2 Antibody | TA-3003-2 | 1mg |
| Tau-9C8 Antibody | TA-3006-1 | 100ug |
| Tau-9C8 Antibody | TA-3006-2 | 1mg |
| Tau-E2+E3 9E11 | TA-3019-1 | 100ug |
| Tau-E2+E3 9E11 | TA-3019-2 | 1mg |
| Tau-E3 2B6 | TA-3018-1 | 100ug |
| Tau-E3 2B6 | TA-3018-2 | 1mg |
| AK-7 | N-3003-1 | 5 mg |
| AK-7 | N-3003-2 | 25 mg |
| ANA-12 | N-3031-1 | 5 mg |
| ANA-12 | N-3031-2 | 25 mg |
| Apomorphine HCI Hemihydrate | N-3027-1 | 100 mg |
| Apomorphine HCI Hemihydrate | N-3027-2 | 500 mg |
| Benztropine Mesylate | N-3012-1 | 1 gm |
| Bexarotene | N-3032-1 | 10 mg |
| Bexarotene | N-3032-2 | 50 mg |
| C-646 | N-3002-1 | 5 mg |
| C-646 | N-3002-2 | 25 mg |
| C16 | N-3030-1 | 5 mg |
| C16 | N-3030-2 | 25 mg |
| Candesartan | N-2049-1 | 20mg |
| Candesartan | N-2049-2 | 100mg |
| Celastrol | N-2187-1 | 10mg |
| Celastrol | N-2187-2 | 50mg |
| CNEE | N-1062-1 | 5mg |
| CNEE | N-1062-2 | 25mg |
| CTPB | N-3001-1 | 5 mg |
| CTPB | N-3001-2 | 25 mg |
| DAPT | N-3018-1 | 5 mg |
| DAPT | N-3018-2 | 25 mg |
| Deoxymannojirimycin HCl | N-2798-1 | 1mg |
| Deoxymannojirimycin HCl | N-2798-2 | 5mg |
| Diazoxide | N-3026-1 | 100 mg |
| Diazoxide | N-3026-2 | 500 mg |
| DMOG | MC-2371-1 | 10mg |
| DMOG | MC-2371-2 | 50mg |
| DU-14 | N-1187-1 | 5mg |
| DU-14 | N-1187-2 | 25mg |
| Edaravone | N-3034-1 | 1 gm |
| Edaravone | N-3034-2 | 5 gm |
| Entacapone | N-2025-1 | 10mg |
| Entacapone | N-2025-2 | 50mg |
| Epoxycholesterol | N-1330-1 | 1mg |
| Epoxycholesterol | N-1330-2 | 5mg |
| Ferrostatin-1 | N-1380-1 | 5mg |
| Ferrostatin-1 | N-1380-2 | 25mg |
| Fingolimod | N-3025-1 | 5 mg |
| Fingolimod | N-3025-2 | 25 mg |
| FK-506 | N-3024-1 | 20 mg |
| FK-506 | N-3024-2 | 100 mg |
| FPS-ZM1 | N-1635-1 | 5mg |
| FPS-ZM1 | N-1635-2 | 25mg |
| Gabapentin lactam | N-2535-1 | 50mg |
| Gabapentin lactam | N-2535-2 | 250mg |
| Imatinib Mesylate | N-3020-1 | 20 mg |
| Imatinib Mesylate | N-3020-2 | 100 mg |
| ISO-1 | N-3017-1 | 10 mg |
| ISO-1 | N-3017-2 | 50 mg |
| ISRIB | N-1539-1 | 5mg |
| ISRIB | N-1539-2 | 25mg |
| ISX9 | N-3010-1 | 5 mg |
| ISX9 | N-3010-2 | 25 mg |
| IU1 | N-1197-1 | 10mg |
| IU1 | N-1197-2 | 50mg |
| LM11A-31 2HCI | N-3005-1 | 5 mg |
| LM11A-31 2HCI | N-3005-2 | 25 mg |
| LM22A-4 | N-3006-1 | 10 mg |
| LM22A-4 | N-3006-2 | 50 mg |
| Minocyline HCI | N-3013-1 | 50 mg |
| Minocyline HCI | N-3013-2 | 250 mg |
| Mithramycin A | N-2085-1 | 1mg |
| Mithramycin A | N-2085-2 | 5mg |
| Mitoquinone | N-1363-1 | 5mg |
| Mitoquinone | N-1363-2 | 25mg |
| Montelukast Sodium | N-3028-1 | 50 mg |
| Montelukast Sodium | N-3028-2 | 250 mg |
| Mycophenolate mofetil | N-2086-1 | 50mg |
| Mycophenolate mofetil | N-2086-2 | 250mg |
| Neurodazine | N-3014-1 | 5 mg |
| Neurodazine | N-3014-2 | 25 mg |
| Neuropathiazol | N-3015-1 | 5 mg |
| Neuropathiazol | N-3015-2 | 25 mg |
| Noopept | N-2682-1 | 10mg |
| Noopept | N-2682-2 | 50mg |
| P7C3 | N-3004-1 | 5 mg |
| P7C3 | N-3004-2 | 25 mg |
| Phenylbutyrate Na | MC-1118-1 | 1gm |
| Phenylbutyrate Na | MC-1118-2 | 5gm |
| Pinacidil | N-2856-1 | 10mg |
| Pinacidil | N-2856-2 | 50mg |
| Prostratin | N-3011-1 | 1 mg |
| Prostratin | N-3011-2 | 5 mg |
| Rapamycin | N-3022-1 | 20 mg |
| Rapamycin | N-3022-2 | 100 mg |
| Resveratrol | N-3019-1 | 100 mg |
| Resveratrol | N-3019-2 | 500 mg |
| Roscovitine | N-1332-1 | 5mg |
| Roscovitine | N-1332-2 | 25mg |
| Salirasib | N-1461-1 | 5mg |
| Salirasib | N-1461-2 | 25mg |
| SB-225022 | N-3016-1 | 5 mg |
| SB-225022 | N-3016-2 | 25 mg |
| Tianeptine | N-3008-1 | 10 mg |
| Tianeptine | N-3008-2 | 50 mg |
| Tolcapone | N-3007-1 | 10 mg |
| Tolcapone | N-3007-2 | 50 mg |
| TRO 19622 | N-3029-1 | 5 mg |
| TRO 19622 | N-3029-2 | 25 mg |
| Vildagliptin | N-2887-1 | 20mg |
| Vildagliptin | N-2887-2 | 100mg |
| Vorinostat | N-3021-1 | 50 mg |
| Vorinostat | N-3021-2 | 250 mg |
| Zileuton | N-3023-1 | 10 mg |
| Zileuton | N-3023-2 | 50 mg |
| Zolmitriptan | N-3033-1 | 10 mg |
| Zolmitriptan | N-3033-2 | 50 mg |

艾美捷科技有限公司代理Complement Technology全系列产品。
Complement Technology公司致力于为生物医学研究提供最高质量的补体试剂。Complement Tech的研发人员在补体相关试剂领域拥有80多年的丰富经验,是补体试剂的原始制造商。
Complement Technology公司的主要产品包括:
| Purified Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C1 (Pure) | A098 | 0.2 | 200 |
| C1q | A099 | 1 | 1000 |
| C1q (40% Glycerol) | A100 | 1 | 1000 |
| C1r Proenzyme | A101 | 0.5 | 100 |
| C1r Enzyme | A102 | 1 | 250 |
| C1s Proenzyme | A103 | 1 | 250 |
| C1s Enzyme | A104 | 1 | 250 |
| C1 Esterase Inhibitor | A140 | 1 | 1000 |
| C1s-C1INH Complex *(NEW)* | C1040 | 0.5 | 50 |
| C2 | A112 | 0.5 | 50 |
| C3 | A113 | 1 | 250 |
| C3 (concentrated) | A113c | 5 | 1000 |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C3b | A114 | 1 | 250 |
| iC3b | A115 | 1 | 250 |
| C3c | A116 | 1 | 250 |
| C3d | A117 | 1 | 100 |
| C4 | A105 | 1 | 250 |
| C4 (concentrated) | A105c | 4 | 1000 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C4b | A108 | 1 | 250 |
| C4b Binding Protein | A109 | 1 | 250 |
| C5 | A120 | 1 | 250 |
| C5a | A144 | 0.5 | 30 |
| C5a (300) | A144(300) | 0.5 | 300 |
| C5a desArg | A145 | 0.5 | 50 |
| C5b,6 | A122 | 0.2 | 50 |
| C6 | A123 | 1 | 250 |
| C7 | A124 | 1 | 250 |
| C8 | A125 | 1 | 250 |
| C9 | A126 | 1 | 250 |
| SC5b-9 Complex | A127 | 1 | 100 |
| Factor B | A135 | 1 | 250 |
| Factor D | A136 | 0.1 | 25 |
| Factor H | A137 | 1 | 250 |
| Factor H (conc.) | A137c | 10 | 10000 |
| Factor I | A138 | 1 | 100 |
| Factor P (Properdin) | A139 | 1 | 100 |
| Cobra Venom Factor (USA Only) | A150 | 1 | 1000 |
| Factor Ba | A154 | 1 | 100 |
| Factor Bb | A155 | 1 | 250 |
| Animal Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| Cyno C3 (USA Only) | CY113 | 1 | 100 |
| Cyno C3b (USA Only) | CY114 | 1 | 100 |
| Mouse C1q | M099 | 1 | 100 |
| Mouse C3 | M113 | 1 | 100 |
| Mouse C3b | M114 | 1 | 100 |
| Rat C1q | R099 | 1 | 100 |
| See Polyclonal Antisera page for Anti-Mouse C3 | M213 | - | - |
| Anaphylatoxin | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C5a | A144 | 0.5 | 30 |
| C5a desArg | A145 | 0.5 | 50 |
| C5a (300) | A144(300) | 0.5 | 300 |
| Complement Assay Reagents | |||
| 产品名称 | 货号 | 体积 | |
| GVBo (without Ca and Mg) - 250ml | B103 | 250ml | |
| GVBo (without Ca and Mg) - 1L | B101 | 1 Liter | |
| GVB++ (with Ca and Mg) - 250ml | B102 | 250ml | |
| GVB++ (with Ca and Mg) - 1L | B100 | 1 Liter | |
| GVBE (with EDTA) - 250ml | B104 | 250ml | |
| GVBE (with EDTA) - 1L | B105 | 1 Liter | |
| SGVB++ (low ionic strength w/Sucrose, Ca and Mg) - 250ml | B110 | 250ml | |
| SGVB++(low ionic strength w/Sucrose, Ca and Mg) - 1L | B111 | 1 Liter | |
| VBS++ (with Ca and Mg) - 250ml | B112 | 250ml | |
| VBS++ (with Ca and Mg) - 1L | B113 | 1 Liter | |
| EA (Ab-sensitized sheep E) - 5ml | B200 | 5ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 10ml | B201 | 10ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 20ml | B202 | 20ml @ 5x10⁸/ml | |
| Es (sheep E) | B210 | 20ml @ 5x10⁸/ml | |
| Er (rabbit E) - 5ml | B300 | 5ml @ 5x10⁸ml | |
| Er (rabbit E) - 10ml | B301 | 5ml @ 5x10⁸/ml | |
| Er (rabbit E) - 20ml | B302 | 20ml @ 5x10⁸/ml | |
| Zymosan (preactivated) | B400 | 10ml @ 1x10⁹/ml | |
| MgEGTA | B106 | 10ml @ 0.1M | |
| MCAR | B250 | 1.0 ml | |
| Hemolysin | Hemolysin | 2.0 ml | |
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Complement Technology"> Complement Technology

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理MicroFIT品牌全系列产品
MicroFIT是一家在生物/医疗领域具有显著影响力的企业,专注于基于模拟人体环境和组织的平台技术,致力于为生物医疗领域提供创新的产品和服务。公司以成为“基于Bio-Convergence技术的仿生平台领先企业”为目标,不断探索和研发,旨在成长为一家提供个性化医疗所需仿生平台的全球性公司。

▍MicroFIT产品线
● StemFIT 3D-Plastic系列
StemFIT 3D-Plastic系列产品采用PS(聚苯乙烯)材料设计,融合了多种实用功能,旨在使大规模3D细胞培养变得更加容易、高效和经济。能广泛应用于再生医学、精准医疗、疾病建模、发育生物学、毒物学、宿主-微生物组相互作用、药物发现和基因编辑等多个领域。
| 型号 | H389600P-6 孔 | H389600P-单人 |
| 材料 | 聚苯乙烯 | 聚苯乙烯 |
| 特征 | 大规模培养, 经济实惠,易于移液, 疏水性 | 大众培养, 经济实惠,易于移液, 疏水性 |
| 井数量 | 每个 2,334 | 389 个 |
| 井径 | 600 微米 | 600 微米 |
| 单元格数量 | ≥ 1.2 x 106 | ≥ 1.2 x 106 |
| 细胞接种培养基的体积 | 1 毫升 | 1 毫升 |
| 细胞培养基体积 | 3 ~ 8 毫升 | 3 毫升 |
| 包装 | 3 包/箱 | 20 个 EA/CS,40 个 EA/CS |
● StemFIT 3D®
StemFIT 3D®是一款创新性的三维细胞培养板,带有凹形微孔的微孔板,其核心原理在于利用这些微孔将孔内的细胞浓缩,进而培养细胞聚集体。使细胞能够在三维空间内相互作用,更好地模拟了体内细胞的生长环境。StemFIT 3D®在三个维度上形成细胞聚集体,允许细胞向各个方向生长并与周围环境相互作用,通过扩散和传递为细胞提供营养、氧气和药物,从而提供更接近生物体真实情况的仿生环境。
| 型号 | 井型 | 井数 | 井径 | 细胞数量 | 播种培养基体积 | 总培养基体积 |
| H1613200 | Hexagon | 1613 | 200 μm | ≥ 6.0 x 105 | 500 μl | 1 ml |
| H853400 | Hexagon | 853 | 400 μm | ≥ 1.2 x 106 | 1 ml | 1.5 ml |
| H389600L/H389600H | Hexagon | 389 | 600 μm | ≥ 1.2 x 106 | 1 ml | H389600L-1.3 ml;H389600H-1.7 ml |
| H449800 | Hexagon | 449 | 800 μm | ≥ 2.4 x 106 | 1 ml | 4 ml |
| H2951000 | Hexagon | 295 | 1000 μm | ≥ 2.4 x 106 | 2 ml | 4 ml |
| C100600 | Circle | 100 | 600 μm | ≥ 6.0 x 105 | 2 ml | 700 μl |
| C163000 | Circle | 16 | 3,000 μm | 2.5 x 105 / well | 20 μl / well | 5 ml |
| C253000 | Circle | 25 | 3,000 μm | 2.5 x 105 / well | 20 μl / well | 3 ml |
● NanoFIT 3D®系列
NanoFIT 3D®系列细胞培养板通过实现线或柱结构的均匀纳米图案来提供仿生界面。这种独特的纳米拓扑结构能够模拟细胞外环境,允许科研人员通过诱导细胞调整其形态和排列,从而更精准地控制和分析特定细胞的反应。它有可能基于纳米图案最大限度地维持和分化细胞,在体内提供类似于ECM(细胞外基质)的环境,使细胞的形态和功能更接近体内真实状态。能维持细胞干性与分化;调节特定细胞靶向;多样化培养形式并且拥有专利技术保障。
| Type | Pattern | Size | Cat. No. |
| Sheet (Polydimethylsiloxane) | Line | 250 nm | N-Line250S |
| Sheet (Polydimethylsiloxane) | Line | 400 nm | N-Line400S |
| Sheet (Polydimethylsiloxane) | Post | 250 nm | N-Post250S |
| Sheet (Polydimethylsiloxane) | Post | 400 nm | N-Post400S |
| Sheet (Polydimethylsiloxane) | Flat | 250 nm | N-Flat250S |
| Sheet (Polydimethylsiloxane) | Flat | 400 nm | N-Flat400S |
| Dish (Polystyrene) | Line | 400 nm | N-Line400P |
● 微珠芯片
微珠芯片是一种专为大规模生产微型珠子而设计的微流控装置。它采用先进的材料和工艺制造,旨在利用胶原蛋白、PEGDA、PLGA等多种水凝胶材料,实现高效、精准的大规模微粒生产。具有卓越的耐化学性;精密的珠子生产能力;材料坚固耐用且可重用。
● PDMS膜
PDMS膜,即聚二甲基硅氧烷膜,作为应用最为广泛的硅基有机聚合物之一,、PDMS膜具有柔软弹性,能够轻松实现大幅度的拉伸变形,且在拉伸过程中仍能保持较好的物理性能和稳定性;具备超薄膜的结构特点,厚度可以做到极薄,在保证基本功能的前提下,最大程度地减少材料的使用和空间的占用;拥有良好的透气性,它允许气体分子自由通过,在生物相容性应用中,能为细胞提供适宜的气体交换环境,促进细胞的生长和代谢;在微流体装置等应用里,也能保证气体的顺畅流通,维持系统的稳定运行;拥有优异的光学透明性,几乎不会对光线的传播产生干扰;对生物组织无毒无害,不会引发明显的免疫反应,可安全地应用于生物医学领域。
<| Material | Diameter | Thickness |
| PDMS | 50 mm / 1.97 inch | 10 μm |
| PDMS | 50 mm / 1.97 inch | 30 μm |
| PDMS | 50 mm / 1.97 inch | 50 μm |
● PDMS定位
PDMS(聚二甲基硅氧烷)作为一种硅基弹性体,拥有高光学透明度,能让研究人员清晰地观察芯片内发生的微观反应和现象;化学稳定性极佳,可在各种化学环境下保持性能稳定;出色的变形性使其能够适应不同的实验需求和操作条件;优异的生物相容性则为生物样本的研究提供了安全可靠的环境。PDMS片上实验室采用了世界领先的PDMS LOC(Lab - on - a - Chip)技术。这项技术实现了在微米尺度上构建具有卓越成型性的纳米·微结构,将复杂的实验室功能集成到一个小小的芯片之上。
● SU-8微型模具
SU-8微型模具是一种感光聚合物模具,专门用于芯片实验室的微图案铸造。它采用环氧树脂基负光刻胶SU-8作为主要材料,通过精密的光刻工艺在晶圆上制造出微图案。相较于其他模具材料,SU-8微型模具的生产速度更快。该模具的高度可高达1,000μm,能够满足制造具有较大高度微结构的需求。这种模具在微流控芯片、生物传感器、微机电系统(MEMS)等领域的生产制造中发挥着重要作用。
| 通道高度 | 晶圆尺寸 | 层 |
| 100 μm 以下 | 4英寸 | 1层 |
| 100 μm 以下 | 6英寸 | 1层 |
| 110 - 200 微米 | 4英寸 | 1层 |
| 110 - 200 微米 | 6英寸 | 1层 |
| 210 - 300 微米 | 4英寸 | 2 层 |
| 310 - 500 微米 | 4英寸 | 超过 2 层 |
| 510 - 800 微米 | 4英寸 | 超过 3 层 |
● 晶圆厂工艺
在半导体产业飞速发展的今天,高效、精准且可靠的制造服务至关重要。MicroFIT凭借其专业的技术和丰富的经验,提供一站式的半导体制造服务,采用分布式外包流程,为客户解决各种制造难题。包括以下服务:
● 光刻:将精心设计的图案精准转移到晶圆上,这是半导体制造的关键起始步骤,为后续的工艺奠定基础,确保图案的高精度和准确性。
● 镀膜:通过各种工艺使金属、聚合物等材料以薄膜形式均匀沉积在硅衬底上,为芯片提供必要的功能层和保护层,增强芯片的性能和稳定性。
● 蚀刻:精确去除必要电路图案外的其余部分,可选择干蚀刻或湿蚀刻方法,以实现对材料的精细加工,塑造出所需的微纳结构。
● 粘接:在半导体制造中,用于将芯片与基板牢固粘合;在微流控器件制造里,用于通道形成后的处理,确保器件各部分之间的可靠连接和密封性。
● 切割:把在半导体晶片加工中制造的器件在图案形成后分离成一定的尺寸,为后续的封装和测试等步骤做准备。
● CMP(化学机械抛光):通过化学和物理过程的结合,对晶圆或玻璃基板进行抛光压平,使表面达到极高的平整度,满足半导体器件制造的严格要求。
" data-original="http://athens.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理MicroFIT品牌全系列产品"> 艾美捷科技代理MicroFIT品牌全系列产品
艾美捷科技有限公司代理SIRIUS FINE CHEMICALS SICHEM GMBH公司产品。
SIRIUS FINE CHEMICALS SICHEM GMBH公司,主要提供:
点击化学工具(Si-CLICK (Click Chemistry))
PEG试剂(Si-PEGs)
脂质及其衍生物(Si-LIPs (Lipids & Derivatives))
磷酸肌醇试剂(Inositol Phosphates & Phosphoinositides)
核酸及其衍生物(Nucleotides & Derivatives)
API标准品及代谢底物(API Standards & Metabolites)
稳定的同位素(Stable Isotopes)
磷酸化及亚磷酸化试剂(Phosphorylation / Phosphitylation)
精细化学试剂(Fine Chemicals)
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
产品列表
| 产品名称 | 产品编号 | 分子式 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4/EQ) / EQUATORIAL isomer | SC-8060 | C15H26N2O4 |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Click Amino Acid / exo-BCN – Fmoc – L - Lysine (BCN) | SC-8038 | C32H36N2O6 |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| Click-Amino-Acid / N3-Lys | SC-8027 | C9H17N5O4 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
| Click Amino Acid / endo-BCN – Fmoc – L - Lysine (BCN) | SC-8015 | C32H36N2O6 |
| Click Amino Acid / trans-Cyclooct-2-en – L - Lysine (TCO*A) | SC-8008 | C15H26N2O4 |
| Click Amino Acid / exo BCN - L - Lysine | SC-8016 | C17H26N2O4 |
| Click Amino Acid / Norbonene-CH2 – L - Lysine (NBO) | SC-8006 | C15 H24 N2 O4 * HCl |
| Click Amino Acid / rac BCN - L - Lysine | SC-8003 | C17H26N2O4 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4) / AXIAL isomer | SC-8004 | C15H26N2O4 |
| Click Amino Acid / endo BCN - L - Lysine | SC-8014 | C17H26N2O4 |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Click Amino Acid (99%) / SCO - L - Lysine - HCO2H-salt | SC-8001 | C15H24N2O4* HCO2H |
| Click Amino Acid (95%) / SCO - L - Lysine - HCO2H-salt | SC-8000 | C15H24N2O4 * HCO2H |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| exo-BCN-NHS carbonate | SC-8075 | C15H17NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| exo BCN - OH | SC-8033 | C10 H14 O |
| SCO - active ester (p-NPE) | SC-8032 | C15H15NO5 |
| SCO - OH | SC-8030 | C8H12O |
| endo BCN - OH | SC-8029 | C10 H14 O |
| exo BCN - active ester (p-NPE) | SC-8010 | C17H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| (E)-cyclooct-4-enol / axial - TCO4 / A | SC-8018 | C8H14O |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| (E)-cyclooct-4-en active ester / TCO/E- active ester (p-NPE) / equatorial | SC-8024 | C15H17NO5 |
| (E)-cyclooct-4-en active ester / TCO4 / A- active ester (p-NPE) / axial | SC-8019 | C15H17NO5 |
| TCO*A - active ester (p-NPE) | SC-8007 | C15H17NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Aminopentyl - Tetrazine - HCl-salt | SC-1193 | C18H20N8O * HCl |
| Tetrazine active ester (Tetrazine-NHS) | SC-1194 | C17H11N7O4 |
| Aminopropyl - Tetrazine - HCl-salt | SC-1192 | C16H16N8O * HCl |
| Methyl-Tetrazine - Amine- HCO2H-salt | SC-1191 | C10H11N5* HCO2H |
| Tetrazine - Amine - HCO2H-salt | SC-1190 | C9H9N5 * HCO2H |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| Bis-Cyano-PEG9 | SC-8932 | C22H40N2O9 |
| Bis-Cyano-PEG5 | SC-8931 | C14H24N2O5 |
| Bis-Cyano-PEG4 | SC-8930 | C12H20N2O4 |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| TAMRA-PEG8-COOH | SC-8711 | C44H59N3O14 |
| TAMRA-PEG4-COOH | SC-8710 | C36H43N3O10 |
| TAMRA-PEG3-COOH | SC-8709 | C34H39N3O9 |
| TAMRA-PEG8-NHS | SC-8708 | C48H62N4O16 |
| TAMRA-PEG4-NHS | SC-8707 | C40H46N4O12 |
| TAMRA-PEG3-NHS | SC-8706 | C38H42N4O11 |
| TAMRA-PEG7-Maleimide | SC-8705 | C48H61N5O14 |
| TAMRA-PEG3-Maleimide | SC-8704 | C40H45N5O10 |
| TAMRA-PEG2-Maleimide | SC-8703 | C38H41N5O9 |
| TAMRA-PEG7-NH2 | SC-8702 | C41H56N4O11 |
| TAMRA-PEG3-NH2 | SC-8701 | C33H40N4O7 |
| TAMRA-PEG2-NH2 | SC-8700 | C31H36N4O6 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Biotin-PEG8-COOH | SC-8611 | C29H53N3O12S |
| Biotin-PEG4-COOH | SC-8610 | C19H33N3O7S |
| Biotin-PEG3-COOH | SC-8609 | C19H33N3O7S |
| Biotin-PEG8-NHS | SC-8608 | C33H56N4O14S |
| Biotin-PEG4-NHS | SC-8607 | C25H40N4O10S |
| Biotin-PEG3-NHS | SC-8606 | C23H36N4O9S |
| Biotin-PEG7-Maleimide | SC-8605 | C33H55N5O12S |
| Biotin-PEG3-Maleimide | SC-8604 | C25H39N5O8S |
| Biotin-PEG2-Maleimide | SC-8603 | C23H35N5O7S |
| Biotin-PEG7-NH2 | SC-8602 | C26H50N4O9S |
| Biotin-PEG3-NH2 | SC-8601 | C18H34N4O5S |
| Biotin-PEG2-NH2 | SC-8600 | C16H30N4O4S |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| PEG-12 | SC-1512 | C24H50O13 |
| PEG-11 | SC-1511 | C22H46O12 |
| PEG-10 | SC-1510 | C20H42O11 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Azido - PEG2 - TCA | SC-0066 | C6H9Cl3N4O2 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Azido - PEG2 - CM | SC-0064 | C5H10ClN3O |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| 2-Methyl-Glycerol | SC-0006 | C4H10O3 |
| 2-Stearoyl glycerol | SC-1171 | C21H42O4 |
| 2-Palmitoyl glycerol | SC-1170 | C19H38O4 |
| 2-Myristoyl glycerol | SC-1169 | C17H34O4 |
| 2-Lauroyl glycerol | SC-1168 | C15H30O4 |
| 2-Linoleoyl glycerol | SC-1167 | C21H38O4 |
| 2-Oleoyl-glycerol | SC-1162 | C21H40O4 |
| SH-6 | SC-0045 | C28H57O9P |
| SH-5 | SC-0044 | C29H59O10P |
| Ins(345)P3*3Na | 3-0-345-Na | C6H12Na3O15P3 |
| Ins(1)P*2K | 1-0-1-2K | C6H11K2O9P |
| myo-Inositol – trispyrophosphate | Pyro-Ins-Na | C6H8Na4O21P6 |
| Ins(123456)P6 | 6-0-123456-Na | C6H18O24P6 * xNa*yH2O |
| Ins(23456)P5*10Na | 5-0-23456-Na | C6H7Na10O21P5 |
| Ins(13456)P5*10Na | 5-0-13456-Na | C6H7Na10O21P5 |
| Ins(12456)P5*10Na | 5-0-12456-Na | C6H7Na10O21P5 |
| Ins(12356)P5*10Na | 5-0-12356-Na | C6H7Na10O21P5 |
| Ins(12345)P5*10Na | 5-0-12345-Na | C6H7Na10O21P5 |
| Ins(1345)P4*8Na | 4-0-1345-Na | C6H8Na8O18P4 |
| Ins(136)P3*6Na | 3-0-136-Na | C6H9Na6O15P3 |
| Ins(134)P3*6K | 3-0-134-K | C6H9K6O15P3 |
| Ins(345)P3*3K | 3-0-345-K | C6H12K3O15P3 |
| Ins(145)P3*6K | 3-0-145-K | C6H9K6O15P3 |
| Ins(145)P3*3Li | 3-0-145-Li | C6H12Li3O15P3 |
| Ins(145)P3*6Na | 3-0-145-Na | C6H9Na6O15P3 |
| Ins(135)P3*6Na | 3-0-135-6Na | C6H9Na6O15P3 |
| Ins(1245)P4*8Na | 4-0-1245-Na | C6H8Na8O18P4 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Bt3-Ins(356)P3 / PM | 3-2-356 | C42H69O30P3 |
| Bt3-Ins(346)P3 / PM | 3-2-346 | C42H69O30P3 |
| Bt3-Ins(146)P3 / PM | 3-2-146 | C42H69O30P3 |
| Bt3-Ins(135)P3 / PM | 3-2-135 | C42H69O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| Bt2-Ins(3456)P4 / PM | 4-2-3456 | C46H76O36P4 |
| Bt2-Ins(1456)P4 / PM | 4-2-1456 | C46H76O36P4 |
| Bt2-Ins(1345)P4 / PM | 4-2-1345 | C46H76O36P4 |
| Bt2-Ins(1356)P4 / AM | 4-1-1356 | C38H60O36P4 |
| Bt3-Ins(356)P3 / AM | 3-1-356 | C36H57O30P3 |
| Bt3-Ins(346)P3 / AM | 3-1-346 | C36H57O30P3 |
| Bt3-Ins(146)P3 / AM | 3-1-146 | C36H57O30P3 |
| Bt3-Ins(134)P3 / AM | 3-1-134 | C36H57O30P3 |
| Bt3-Ins(136)P3 / AM | 3-1-136 | C36H57O30P3 |
| Bt3-Ins(135)P3 / AM | 3-1-135 | C36H57O30P3 |
| Bt3-Ins(145)P3 / AM | 3-1-145 | C36H57O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| caged-Ins(145)P3O6 | cag-6-145 | C15H18NO19P3Na6 |
| caged-Ins(145)P3 P4 | cag-0-145 | C14H19NO17P3Na3 |
| PtdIns(345)P3 | Ptd-0-345-16 | C41H82O22P4 |
| PtdIns(45)P2 | Ptd-0-45-16 | C41H81O19P3 |
| PtdIns(34)P2 | Ptd-0-34-16 | C41H81O19P3 |
| PtdIns(5)P | Ptd-0-5-16 | C41H80O16P2 |
| PtdIns(4)P | Ptd-0-4-16 | C41H80O16P2 |
| PtdIns(3)P | Ptd-0-3-16 | C41H80O16P2 |
| PtdIns(1)P | Ptd-0-1-16 | C41H79O13P |
| D-myo-Inositol-1,2-O-cyclohexylidene | SC-0088 | C12H20O6 |
| 23:45- diisopropylidene-myo-Inositol | SC-0079 | C12H20O6 |
| 12:56- diisopropylidene-myo-Inositol | SC-0078 | C12H20O6 |
| D-myo-Inositol-2,3-O-cyclohexylidene | SC-0077 | C12H20O6 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| 2,3:4,5-Di-O-Iso-1,6-Di-O-Benzyl-Ins | IOB-Ins-2345 | C26H32O6 |
| 1,2:5,6-Di-O-Iso-3,4-Di-O-Benzyl-Ins | IOB-Ins-1256 | C26H32O6 |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| DEAC-dUTP | SC-9002 | C26H31N4O17P3 |
| 35-PAPS-TEA | SC-9000-TEA | C10H15N5O13P2S x 4 C6 H15 N |
| ACPPS-TEA | SC-0068 | C10H13N5O12P2S + C6H5N |
| 25-PAPS-Li | SC-9001-Li | C10H11Li4N5O13P2S |
| 35-PAPS-Li (CAS: 102029-54-9) | SC-9000-Li | C10H11Li4N5O13P2S |
| EdU | SC-0040 | C11H12N2O5 |
| EdUTP-TEA | SC-0039 | C11H15N2O14P3 * 4(C6H15N) |
| EdUTP | SC-0038 | C11H15N2O14P3 |
| 2'-PAP | SC-0037 | C10H17N5O10P2 |
| 2'-PAP-Na | SC-0036 | C10H15N5Na2O10P2 |
| 3'-PAP-Na | SC-0034 | C10H15N5Na2O10P2 |
| 3'-PAP | SC-0035 | C10H17N5O10P2 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Didechloro Vancomycin | SC-1605 | C66H77N9O24 |
| Vancomycin Impurity A | SC-1601 | C65H73Cl2N9O24 |
| Vancomycin Impurity D | SC-1604 | C59H62Cl2N8O22 |
| Vancomycin Impurity C | SC-1603 | C53H52Cl2N8O17 |
| Vancomycin Impurity B | SC-1602 | C66H74Cl2N8O25 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Podophyllotoxin Derivate | SC-0025 | C21H20O8 |
| Podophyllotoxin Derivate | SC-0026 | C21H21NO7 |
| Clopidogrel Impurity 4 | SC-0099 | C16H16ClNO2S * H2SO4 |
| Gestodene Impurity E | SC-0028 | C21H24O3 |
| Fidaxomicin Metabolite OP-1118 | SC-1158 | C48H68Cl2O17 |
| Prasugrel metabolite M6-d3 (stabilzed) | SC-0093 | C27H25D3FNO5S * HCl |
| Prasugrel metabolite M6 | SC-0092 | C19H22FNO3S |
| Clopidogrel Impurity C | SC-0087 | C16H18ClNO2S |
| Clopidogrel Impurity 3 | SC-0086 | C15H17Cl2NO2S |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| Prasugrel active metabolite M3 HCl (stabilized) | SC-0029 | C27H28FNO5S * HCl |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Methyl 4-(2-hydroxyethyl)benzoate-13C6,2D (Ring-13C6,Ethyl-1,2-D2) | SC-0080 | C4 13C6 H10 D2 O3 |
| Anthracene 13C6 | SC-0074 | 13C6C8H8 |
| Phenanthrene 13C6 | SC-0073 | 13C6C8H8 |
| Naphthalene 13C10 | SC-0072 | 13C10H8 |
| Naphthalene 13C6 | SC-0071 | 13C6C4H8 |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite | SC-0091 | C9H18ClN2OP |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(2-cyanoethyl) ester | SC-0061 | C12H22N3O2P |
| Phosphoramidous acid, N,N-bis(1-methylethyl)-, bis(phenylmethyl) ester | SC-1165 | C20 H28 N O2 P |
| Phosphorodiamidous acid. N.N.N'.N'-tetrakis(1-methylethyl)-. phenylmethyl ester | SC-0060 | C19 H35 N2 O P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. 2-cyanoethyl [1-(2-nitrophenyl)ethyl] ester) | SC-0059 | C17 H26 N3 O4 P |
| Dichloro N,N-Diisopropylphosphoramidite | SC-0058 | C6 H14 Cl2 N P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(9H-fluoren-9-ylmethyl) ester | SC-0057 | C34 H36 N O2 P |
| Di-tert-butyl chloromethyl phosphate | SC-0011 | C9H20ClO4P |
| Di-benzyl chloromethyl phosphate | SC-0010 | C15H16ClO4P |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| D-Serine-O-phosphate | SC-1810 | C3H8NO6P |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Menaquinone 8 / MK 8:8 | SC-1230 | C51H72O2 |
| Allyl-Maleimide | SC-1121 | C7H7NO2 |
| Nor-cisapride Derivative | SC-1161 | C17H25Cl2N3O3 |
| AlK - L - Lysine - HCl-salt | SC-8012 | C10H18N2O4* HCl |
| 4-methyl-2,2-bis(trifluoromethyl)oxazolidin-5-one | SC-0098 | C6H5F6NO2 |
| 3-(5-oxo-2,2-bis(trifluoromethyl)oxazolidin-4-yl)propanoic acid | SC-0097 | C8H7F6NO4 |
| 7-(diethylamino)-4-(hydroxymethyl)-coumarin / DEACM | SC-0096 | C14H17NO3 |
| 3-bromo-4-methyl-7-(diethylamino)-coumarin | SC-0095 | C14H16BrNO2 |
| Xanthohumol | SC-0094 | C21H22O5 |
| IEPOX 4 | SC-0090 | C5H10O3 |
| IEPOX 3 | SC-0089 | C5H10O3 |
| 2-C-Methyl-L-Threitol | SC-0085 | C5H12O4 |
| 2-C-Methyl-D-Threitol | SC-0084 | C5H12O4 |
| 2-C-Methyl-L-Erythritol | SC-0083 | C5H12O4 |
| 2-C-Methyl-D-Erythritol | SC-0082 | C5H12O4 |
| 3-Amino-7-(diethylamino)-coumarine | SC-0081 | C13 H16 N2 O2 |
| Chloromethylpropionate | SC-1164 | C4H7ClO2 |
| 2-(2-fluoro-2-methylpropoxy)-2-methylpropan-1-ol | SC-1163 | C8H17FO2 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| Y-27632 | SC-0048 | C14H21N3O *2HCl |
| H-1152 | SC-0053 | C16H21N3O2S*2HCl |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| TCO* - NHS carbonate / EQUATORIAL isomer | SC-8071 | C13H17NO5 |
| TCO* - NHS carbonate / AXIAL isomer | SC-8070 | C13H17NO5 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:18771149750
邮箱:sales@amyjet.com
0.3868